• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical Development

    6/5/23 4:35:00 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JANX alert in real time by email

    Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Dr. Zachariah ("Zach") McIver as Vice President, Clinical Development. An accomplished physician-scientist with more than 15 years of experience in clinical research, Dr. McIver joins Janux after serving as Amgen's Executive Medical Director, where he led cross-functional teams in the design, implementation, and execution of clinical and correlative study strategies.

    "Zach has extensive clinical research experience including leading the clinical development to maximize the value of bispecific T-cell engager assets across multiple hematologic and solid tumor malignancies," said David Campbell, Ph.D., President and CEO of Janux Therapeutics. "At Janux, Zach will play a key role in clinical development oversight as we advance our novel immunotherapy programs through clinical trials."

    "We're excited to have Zach join the team as his experience with advanced T-cell engager programs will be especially important as we continue to advance our drug candidates in clinical trials," said Wayne Godfrey, M.D., Chief Medical Officer at Janux.

    "With TRACTr and TRACIr, Janux has built two very powerful platforms designed to overcome the toxicity and efficacy limitations of earlier generations of bispecific immunotherapies," said Dr. McIver. "I look forward to working with the team at Janux to advance the Company's deep portfolio of next-generation bispecific immunotherapies to improve cancer treatment and help more patients."

    A board-certified hematologist and physician-scientist, Dr. McIver began his career specializing in hematological malignancies and immunotherapy working as a principal investigator at the Hematology Branch of the National Heart, Lung, and Blood Institute (NHLBI) at the National Institute of Health (NIH). He played a key role in developing novel small molecules targeting alloreactive T-cells to prevent graft-versus-host-disease (GVHD) and established a stem cell transplant program for racial minority populations at the Wake Forest University School of Medicine. Dr. McIver also served as an attending physician at Wake Forest in the hematology/oncology department. Prior to this, he was an attending physician and a research investigator in the department of hematology/oncology at Tulane University School of Medicine.

    Dr. McIver earned a B.S. in Physics and General Sciences from the University of Oregon, a Doctor of Osteopathic Medicine (D.O.) from Ohio University College of Osteopathic Medicine and a Ph.D. in Molecular Medicine and Translational Sciences at the Wake Forest University School of Medicine. He completed his internal medicine residency at the Cleveland Clinic, and his clinical fellowship in hematology and oncology at the NHLBI at the NIH. In addition, Dr. McIver is an active member of professional societies such as the American Society of Clinical Oncology, American Society of Hematology, and American College of Physicians.

    Janux's TRACTr and TRACIr Pipeline

    JANX008 is a TRACTr that targets epidermal growth factor receptor (EGFR) and is being studied in a Phase 1 clinical trial for the treatment of multiple solid cancers including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Janux's first clinical candidate, JANX007, is a TRACTr that targets prostate-specific membrane antigen (PSMA) and is being investigated in a Phase 1 clinical trial in adult subjects with metastatic castration-resistant prostate cancer (mCRPC). Janux's TRACIr drug candidate, JANX009, is designed for targeting both the programmed death-ligand 1 (PD-L1) receptor as well as the costimulatory CD28 receptor on T cells and is being investigated in preclinical studies for the treatment of solid tumors. Janux is also applying its proprietary technology to develop a TRACTr designed to target trophoblast cell surface antigen 2 (TROP2), a clinically validated anti-tumor target that is overexpressed in various cancer types, such as breast, lung, urothelial, endometrial, ovarian, prostate, pancreatic, gastric, colon, head and neck, and glioma. In addition to named programs, Janux is generating a number of unnamed TRACTr and TRACIr programs for potential future development.

    About Janux Therapeutics

    Janux is a clinical-stage biopharmaceutical company developing next-generation bispecific immunotherapies with the goal of fighting cancers by killing tumor cells while allowing healthy tissues to remain unharmed. Janux's proprietary platforms develop unique Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) and support the building of a broad pipeline of drugs designed to direct and guide the patient's immune system to eradicate tumors while minimizing safety concerns. The company's innovative technology currently focuses on the engineering of bispecific antibodies functional only in the tumor, designed to provide safety advantages compared to earlier generations of bispecific immunotherapies. Currently, Janux's two lead TRACTr compounds for PSMA and EGFR are in the clinic. For more information, please visit www.januxrx.com and follow us on LinkedIn.

    Forward-Looking Statements

    This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, Janux's ability to bring new treatments to cancer patients in need, expectations regarding the timing, scope and results of Janux's development activities, including its ongoing and planned clinical trials, the timing of and plans for regulatory filings, the potential benefits of Janux's product candidates and platform technologies, and expectations regarding the use of Janux's platform technologies to generate novel product candidates. Factors that may cause actual results to differ materially include the risk that compounds that appear promising in early research do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Janux may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings and applications, risks associated with reliance on third parties to successfully conduct clinical trials, the risks associated with reliance on outside financing to meet capital requirements, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "promise," "potential," "expects," "plans," "anticipates," "intends," "continues," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties Janux faces, please refer to Janux's periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Janux assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230605005059/en/

    Get the next $JANX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $JANX

    DatePrice TargetRatingAnalyst
    7/11/2025$65.00Outperform
    Raymond James
    12/3/2024$82.00 → $100.00Buy
    BTIG Research
    12/3/2024$63.00 → $70.00Buy
    H.C. Wainwright
    11/22/2024$79.00Outperform
    Leerink Partners
    10/24/2024$69.00Buy
    UBS
    9/6/2024$70.00Buy
    Stifel
    5/30/2024$47.00Sector Perform
    Scotiabank
    3/21/2024$62.00Buy
    BTIG Research
    More analyst ratings

    $JANX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day

      PSMA-TRACIr designed to be combined with potentially best-in-treatment asset, JANX007, and provide CD28 co-stimulation to further differentiate depth and durability of patient responses. TROP2-TRACTr adds first-in-class and best-in-class opportunity targeting multiple solid tumors with preclinical data supporting differentiated safety and efficacy potential. CD19-ARM displayed rapid, deep and durable B-cell depletion in periphery and tissues with a prolonged memory B cell reset while maintaining a large safety window in non-human primates, advancing toward first-in-human trials anticipated to begin in the first half of 2026. Webcast to be held today at 1:30 PM PT. Janux Therape

      7/24/25 4:05:00 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Janux Therapeutics to Host Virtual R&D Day on July 24, 2025

      Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that it will host a virtual R&D Day at 1:30 PM PT on Thursday, July 24, 2025. The event will include a presentation from management highlighting product candidates identified from its preclinical pipeline to move into clinical trials. These previously undisclosed preclinical programs utilize Janux's expertise and platform technologies to potentially address significant unmet medical needs.

      7/17/25 4:30:00 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer

      Ms. Doyle brings more than two decades of corporate strategy and business development experience across biotech, pharma, and venture ecosystems Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Janeen Doyle, MBA, as Chief Corporate and Business Development Officer. "Janeen's unique blend of corporate development, strategic execution, and clinical insight makes her an ideal leader to help drive the next phase of growth at J

      5/15/25 8:00:00 AM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JANX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Raymond James initiated coverage on Janux Therapeutics with a new price target

      Raymond James initiated coverage of Janux Therapeutics with a rating of Outperform and set a new price target of $65.00

      7/11/25 8:13:15 AM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research reiterated coverage on Janux Therapeutics with a new price target

      BTIG Research reiterated coverage of Janux Therapeutics with a rating of Buy and set a new price target of $100.00 from $82.00 previously

      12/3/24 7:52:53 AM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright reiterated coverage on Janux Therapeutics with a new price target

      H.C. Wainwright reiterated coverage of Janux Therapeutics with a rating of Buy and set a new price target of $70.00 from $63.00 previously

      12/3/24 7:50:21 AM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JANX
    Leadership Updates

    Live Leadership Updates

    See more
    • Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day

      PSMA-TRACIr designed to be combined with potentially best-in-treatment asset, JANX007, and provide CD28 co-stimulation to further differentiate depth and durability of patient responses. TROP2-TRACTr adds first-in-class and best-in-class opportunity targeting multiple solid tumors with preclinical data supporting differentiated safety and efficacy potential. CD19-ARM displayed rapid, deep and durable B-cell depletion in periphery and tissues with a prolonged memory B cell reset while maintaining a large safety window in non-human primates, advancing toward first-in-human trials anticipated to begin in the first half of 2026. Webcast to be held today at 1:30 PM PT. Janux Therape

      7/24/25 4:05:00 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Janux Therapeutics to Host Virtual R&D Day on July 24, 2025

      Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that it will host a virtual R&D Day at 1:30 PM PT on Thursday, July 24, 2025. The event will include a presentation from management highlighting product candidates identified from its preclinical pipeline to move into clinical trials. These previously undisclosed preclinical programs utilize Janux's expertise and platform technologies to potentially address significant unmet medical needs.

      7/17/25 4:30:00 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer

      Ms. Doyle brings more than two decades of corporate strategy and business development experience across biotech, pharma, and venture ecosystems Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Janeen Doyle, MBA, as Chief Corporate and Business Development Officer. "Janeen's unique blend of corporate development, strategic execution, and clinical insight makes her an ideal leader to help drive the next phase of growth at J

      5/15/25 8:00:00 AM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JANX
    Financials

    Live finance-specific insights

    See more
    • Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs

      Multiple patients treated with PSMA-TRACTr JANX007 have achieved meaningful PSA drops coupled with manageable safety and CRS PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008 have been generally well tolerated at levels above the projected maximum tolerable dose of the parental T cell engagers JANX007 preliminary data showed encouraging safety results consistent with on-tumor activity with no dose-limiting toxicities PK exposure demonstrated TRACTr activation with lack of TCE accumulation No treatment-emergent ADA titers observed Janux to host virtual investor event today at 4:00 PM Eastern Time Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutica

      7/17/23 8:00:00 AM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JANX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Janux Therapeutics Inc.

      SC 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)

      11/14/24 4:24:38 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Janux Therapeutics Inc.

      SC 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)

      11/14/24 4:17:06 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Janux Therapeutics Inc.

      SC 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)

      11/14/24 4:01:49 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JANX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ra Capital Management, L.P. was granted 3,750 shares (SEC Form 4)

      4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

      6/13/25 7:33:08 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Dobmeier Eric was granted 3,750 shares, increasing direct ownership by 60% to 9,981 units (SEC Form 4)

      4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

      6/13/25 7:30:18 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Gujrathi Sheila was granted 3,750 shares, increasing direct ownership by 3% to 118,889 units (SEC Form 4)

      4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

      6/13/25 7:30:17 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JANX
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Janux Therapeutics Inc.

      SCHEDULE 13G - Janux Therapeutics, Inc. (0001817713) (Subject)

      7/17/25 7:54:40 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Janux Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Janux Therapeutics, Inc. (0001817713) (Filer)

      6/13/25 4:35:34 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Janux Therapeutics Inc.

      SCHEDULE 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)

      5/14/25 12:25:43 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JANX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ra Capital Management, L.P. bought $25,342,965 worth of shares (824,041 units at $30.75) (SEC Form 4)

      4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

      3/7/25 6:05:32 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ra Capital Management, L.P. bought $53,700,000 worth of shares (1,200,000 units at $44.75) (SEC Form 4)

      4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

      10/22/24 4:20:04 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Reardon Tighe bought $4,988,643 worth of shares (849,854 units at $5.87) (SEC Form 4)

      4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

      11/15/23 4:48:17 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care